M. D. I. Uddin

Array ( [id] => 13748815 [patent_doc_number] => 10167339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Antagonistic anti-OX40L antibodies and methods of their use [patent_app_type] => utility [patent_app_number] => 15/501526 [patent_app_country] => US [patent_app_date] => 2015-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 27 [patent_no_of_words] => 26767 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15501526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11003877 [patent_doc_number] => 20160200826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'Anti-Jagged 1/Jagged 2 Cross-Reactive Antibodies, Activatable Anti-Jagged Antibodies And Methods Of Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/815167 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 72694 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10996386 [patent_doc_number] => 20160193332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'Activatable Antibodies That Bind Epidermal Growth Factor Receptor And Methods Of Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/815111 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 66723 [patent_no_of_claims] => 70 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10662335 [patent_doc_number] => 20160008480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'FUSION PROTEIN COMPRISING TARGETING MOIETY, CLEAVAGE SITE, AND CELL MEMBRANE PENETRATING DOMAIN, AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/794542 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 14809 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14794542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12912640 [patent_doc_number] => 20180196056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => PREDICTIVE BASELINE BIOMARKERS FOR USE OF VASCULAR DISRUPTING AGENTS [patent_app_type] => utility [patent_app_number] => 15/323151 [patent_app_country] => US [patent_app_date] => 2015-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19022 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15323151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11852059 [patent_doc_number] => 20170226552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'METHODS FOR MODULATING PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS USING COBALT' [patent_app_type] => utility [patent_app_number] => 15/320522 [patent_app_country] => US [patent_app_date] => 2015-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 30269 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15320522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10416047 [patent_doc_number] => 20150301055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'CIRCULATING BIOMARKERS FOR DISEASE' [patent_app_type] => utility [patent_app_number] => 14/789729 [patent_app_country] => US [patent_app_date] => 2015-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 257 [patent_figures_cnt] => 257 [patent_no_of_words] => 208064 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14789729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11547282 [patent_doc_number] => 09616105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-11 [patent_title] => 'Agent for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory T cells' [patent_app_type] => utility [patent_app_number] => 14/752726 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 9586 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14752726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851707 [patent_doc_number] => 20170226199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'ANTI-TNF ALPHA ANTIBODIES WITH PH-DEPENDEND ANTIGEN BINDING FOR IMPROVED TARGET CLEARENCE' [patent_app_type] => utility [patent_app_number] => 15/322893 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9482 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15322893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051210 [patent_doc_number] => 20170327553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'COMPOSITIONS AND METHODS FOR LONG ACTING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/321065 [patent_app_country] => US [patent_app_date] => 2015-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 43833 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15321065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10483343 [patent_doc_number] => 20150368362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-24 [patent_title] => 'ANTI-HISTONE THERAPY FOR VASCULAR NECROSIS IN SEVERE GLOMERULONEPHRITIS' [patent_app_type] => utility [patent_app_number] => 14/746997 [patent_app_country] => US [patent_app_date] => 2015-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 26758 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14746997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10499620 [patent_doc_number] => 09228016 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-05 [patent_title] => 'Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/732082 [patent_app_country] => US [patent_app_date] => 2015-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 102 [patent_figures_cnt] => 147 [patent_no_of_words] => 89467 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14732082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10661488 [patent_doc_number] => 20160007632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'METHOD OF USE OF ACTIVATED FUNCTIONAL PROTEINS TO IMPROVE ANIMAL HEALTH' [patent_app_type] => utility [patent_app_number] => 14/731648 [patent_app_country] => US [patent_app_date] => 2015-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3486 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14731648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13179961 [patent_doc_number] => 10105469 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Composition-of-matter and method for treating cardiovascular disorders [patent_app_type] => utility [patent_app_number] => 14/730282 [patent_app_country] => US [patent_app_date] => 2015-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 28 [patent_no_of_words] => 10225 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14730282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678032 [patent_doc_number] => 20160024176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'OX40L FUSION PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/722679 [patent_app_country] => US [patent_app_date] => 2015-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 46327 [patent_no_of_claims] => 90 [patent_no_of_ind_claims] => 39 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14722679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635689 [patent_doc_number] => 09353183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Methods for treating and/or limiting development of diabetes' [patent_app_type] => utility [patent_app_number] => 14/717903 [patent_app_country] => US [patent_app_date] => 2015-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14004 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14717903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422612 [patent_doc_number] => 20150307624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/702143 [patent_app_country] => US [patent_app_date] => 2015-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6891 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14702143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10412664 [patent_doc_number] => 20150297672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'Alpha- and gamma-MSH analogues' [patent_app_type] => utility [patent_app_number] => 14/693822 [patent_app_country] => US [patent_app_date] => 2015-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 47534 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14693822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11444491 [patent_doc_number] => 20170045512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'METHODS FOR THE DIAGNOSTIC OF AN AUTOIMMUNE DISEASE' [patent_app_type] => utility [patent_app_number] => 15/305548 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8932 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11428010 [patent_doc_number] => 09566314 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-14 [patent_title] => 'Extracellular vesicles comprising recombinant lysosomal transmembrane protein' [patent_app_type] => utility [patent_app_number] => 14/692109 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 21 [patent_no_of_words] => 12023 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14692109 [rel_patent_id] =>[rel_patent_doc_number] =>)